Karo Pharma acquires Reckitt's dermatology brand E4

Around one month after announcing the EUR 290m acquisition of Sylphar, Swedish Karo Pharma has once again taken out the big chequebook to acquire access to dermatology brand E45.

Photo: Karo Pharma / PR

Since 2019, Swedish Karo Pharma has completed acquisitions for over USD 1.5bn (DKK 10bn), and yet it seems the thirst for new assets hasn't been quenched.

On Dec. 24, the firm announced an agreement for the potential acquisition of Reckitt's dermatology brand E45, a line of skincare products. The takeover's price tag reads GBP 200m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs